 |
Decentralized clinical trials (DCTs) have grown substantially over the past few years. Today’s biopharma companies are increasingly leaning on virtual tools to make remote trials a fixed part of their portfolios. This expanding footprint in turn enables anyone, anywhere, to participate in a clinical trial. As sponsors make sense of the new tech ecosystem supporting remote trials, they’re encountering a critical question: should they structure their DCT portfolio as a full-service approach (all-in-one), or one that engages best-of-breed/functional service providers (FSPs)? Designed for biopharma leaders, our playbook will unveil questions to ask when comparing DCT partners. You will discover:
|
